We are leveraging our unique and proven CRISPR-based platform to discover new targets and develop unique cell therapies, initially focusing on engineered tumor-infiltrating lymphocytes (eTILs®) to treat solid-tumor cancers.
Our bold ambition
IMPACT EVERY PATIENT
by initially focusing on cell therapies with curative potential across a broad array of solid tumor cancers.
Improve the patient experience
by transforming cell therapy approaches to alleviate the burdens associated with current treatment paradigms.
Maximize patient response
by developing personalized, engineered cell therapies with the promise to address high unmet medical needs.